The purpose of the current study was to comprehensively explore the relation between composition of the gut microbiome and lifetime CVD risk profile among a subsample of 55 Bogalusa Heart Study (BHS) participants with the highest and 57 with the lowest lifetime burdens of traditional CVD risk factors. This study leveraged carefully collected data from an average of 9 participant visits obtained during 
T he human gut hosts a vast array of microbes collectively known as the microbiota. Although influences of the gut microbiota on human health have been hypothesized for some time, only in the past decade have advances in technology made it feasible to comprehensively characterize host microbial communities and examine their associations with disease states. 1, 2 With growing evidence for a critical role of the gut microbiome in energy harvest, 3 glucose and lipid metabolism, 4, 5 and systemic inflammation, 5 a potential influence of this commensal supraorganism on cardiovascular disease (CVD) development has been hypothesized. Indeed, the cross-sectional relationships of the gut microbiota with certain CVD risk factors, including obesity, 6, 7 type 2 diabetes mellitus, 8, 9 and dyslipidemia, 10, 11 have already been documented. Gut microbiota have also been shown to be integral in the derivation of the trimethylamine metabolite from certain marine fish, as well as from foodstuffs or supplements rich in phosphatidylcholine (lecithin), free choline, and carnitine. [12] [13] [14] Trimethylamine is the dietary-derived precursor to trimethylamine-N-oxide, 15 a metabolite that was recently linked prospectively to CVD.
14 These data suggest a potentially important role of the human gut microbiome in CVD development. However, few studies have systematically assessed the influence of gut microbiota composition on overall CVD risk.
follow-up to profile CVD risk from childhood through adulthood. Furthermore, potential confounders such as age, sex, race, body mass index (BMI), and diet were controlled in the analyses.
Methods

Study Participants
The BHS is a long-term, epidemiological study investigating the natural history of atherosclerosis among a biracial sample (35% black and 65% white) of residents from Bogalusa, Louisiana, begun in 1973 by Dr Gerald Berenson. From 1973 to 2016, 7 surveys of children aged 4 to 17 years and 10 surveys of adults aged 18 to 50 years, who had been examined previously as children, were conducted. The current BHS cohort includes 1298 participants born between 1959 and 1979 who were screened at least 2 times during childhood and 2 times during adulthood for CVD risk factors. A subsample of 203 participants from this cohort who were at highest and lowest estimated lifetime risk of CVD were contacted to determine eligibility for participation in the microbiome study. After excluding 42 participants who had taken antibiotics or probiotics in the past 2 months, 161 met the eligibility criteria for enrollment. One hundred and twelve of these participants (37% black and 63% white), including 55 with high lifetime CVD risk profile and 57 with low lifetime CVD risk profile, agreed to participate and returned stool specimens for subsequent microbiome characterization and analyses (response rate of 70%).
Informed consents were obtained from all the Bogalusa Heart Study participants after detailed explanation of the study. The study was approved by the Institutional Review Boards at all the participating institutions.
Measurement of CVD Risk Factors in the BHS Cohort
All BHS examinations have followed nearly identical study protocols. 16, 17 During each study visit, blood pressure (BP) was measured in the morning in triplicate by each of 2 trained observers using a mercury sphygmomanometer with the participant in a relaxed, sitting position. Systolic BP (SBP) and diastolic BP levels were measured as the first and fourth (in children) or fifth (in adults) Korotkoff sounds, respectively. The mean of the 6 BP values were used to estimate BP at each study visit. Anthropometric measures were obtained by trained staff, with BHS participants in light clothing without shoes. Height and weight were measured in duplicate to the nearest 0.1 cm and 0.1 kg, respectively. The mean of height and weight were used to estimate BMI at each study visit. Diet information was collected at 2 time points in young adulthood using a validated food frequency questionnaire. 18 Participants were instructed to fast for 12 hours before blood sample collection. During 1973 to 1986, cholesterol and triglyceride levels were measured by the use of chemical procedures with a Technicon AutoAnalyzer II (Technicon Instrument Corporation, Tarrytown, NY) according to the Laboratory Manual of the Lipid Research Clinics Program. Since 1987, these variables were determined using the Abbott VP instrument (Abbott Laboratories, North Chicago, IL) and on the Hitachi 902 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN) afterward by enzymatic procedures. 19 Serum lipoprotein cholesterols were analyzed using a combination of heparin-calcium precipitation and agar-agarose gel electrophoresis procedures. 20 Plasma glucose was measured initially by a glucose oxidase method using a Beckman Instant Glucose Analyzer (Beckman Instruments, Palo Alto, CA). After 1991, glucose was measured in adults using a multichemistry (SMA20) profile by enzymatic procedures using the multichannel Olympus Au-5000 Analyzer (Olympus, Lake Success, NY).
Estimation of Lifetime CVD Risk Profile
Lifetime CVD risk profile was estimated based on the average of fasting plasma glucose, SBP, and low-density lipoprotein (LDL) cholesterol values from at least 4 BHS study visits conducted from childhood to adulthood. Lifetime CVD risk groups were identified using a Z score-based data reduction technique. For each participant, Z scores for mean lifetime measures of glucose, SBP, and LDL cholesterol were generated. Z scores for each risk factor were then summed to create an overall lifetime CVD risk score for each participant. Participants were ranked according to risk score, and those with the highest and lowest scores were contacted for participation in the current study.
Microbiome Sequencing and Analysis
Fecal samples were collected at the homes of study participants and returned to BHS investigators within 24 hours of collection, at which time they were stored at −80 °C until microbiome characterization. Using methods developed for the Human Microbiome Project, DNA isolation and microbiome sequencing were conducted at the Baylor College of Medicine's Alkek Center for Metagenomics and Microbiome Research. 21, 22 Briefly, genomic bacterial DNA was extracted from fecal samples using the MO BIO PowerSoil DNA Isolation Kit (MO BIO Laboratories, Inc, Carlsbad, CA). The 16S rDNA V4 hypervariable region was then amplified by polymerase chain reaction and sequenced on the MiSeq platform using the 2×250 bp paired-end protocol (Illumina, San Diego, CA). 23 The read pairs were demultiplexed based on their unique molecular barcodes and overlapping reads were merged using USEARCH v7.0.1001 software. 24 Operational taxonomic unit (OTU) picking was conducted using the QIIME (Quantitative Insights Into Microbial Ecology) software package.
25
16S ribosomal RNA gene sequences were clustered at a similarity cutoff value of 97% using UCLUST. 24 Matching of OTUs to bacteria was then conducted using the SILVA reference database. 26 Abundances were recovered by mapping the demultiplexed reads to the identified OTUs.
Because sequencing depth ranged from 4118 to 13 146 reads per sample, library size was rarefied to the minimum read depth. Subsequently, several α diversity measures were estimated based on identified OTUs. 27 Microbial richness, which measures the number of taxa in each sample (or the abundance of microbes), was examined by calculating the number of observed OTUs, Chao 1 index, and abundance-based coverage estimator. 28 Evenness, which measures the relative number of taxa in samples (accounting for the number of times each taxon was observed in a sample), was additionally assessed using the Shannon, Simpson, and inverse Simpson indices. 27 An additional quality control step was then conducted to restrict analyses to only those 116 OTUs, which comprised ≥0.05% of reads and were present in at least 5% of samples. These OTUs accounted for an average of 95% of total reads per sample. The 116 OTUs were assigned to 75 genera, which were examined in further analyses. The distribution of microbiome data before and after rarefying and quality filtering are shown in Online Figure II . Processing of microbiome sequence data was conducted using the phyloseq package (V1.15.14) in R. 28 
Statistical Analysis
Lifetime CVD risk groups were compared on pertinent characteristics with the use of χ 2 tests for categorical variables and t tests for continuous variables. All α diversity measures were examined for normality and log transformed as needed.
Logistic regression models were used to examine the associations between each measure of α diversity and lifetime CVD risk profile 29 To accommodate the excessive zero counts and overdispersion of microbiome data, in step 1, a zeroinflated negative binomial model was used to model each genus. 30 This model assumes that microbiome data for each genus are from a mixture of 2 separate distributions, one from a negative binomial distribution and the other from a constant distribution generating only zero counts. We model both negative binomial data and the zero count data (the probability of being a zero count) simultaneously with important covariables treated as predictors. The log-transformed total genus counts, which varied slightly between participants because of the additional quality control steps subsequent to rarefication, were included in the model as the offset variable. In step 2, the raw residuals from these models, representing the independent effects of each genus, were then compared between CVD risk groups using the Wilcoxon rank-sum test. A Bonferroni correction for the 75 genera tested was used using an α threshold of 6.67×10 −4 to determine statistical significance.
Three multivariable adjustments were used to test associations of both α diversity estimates and individual genera with lifetime CVD risk profile. Model 1 adjusted for age, sex, and race. To examine the potentially mediating influence of BMI, a second model adjusting for age, sex, race, and BMI was also assessed (model 2). To determine whether identified associations were consistent after adjustment for dietary factors in this relatively small sample, a third model adjusting for age, sex, race, BMI, total energy intake, and energy-adjusted 31 intakes of dietary protein, animal fat, and fiber was examined.
Results
Lifetime CVD risk profiles were estimated using an average of 9 measures of glucose, SBP, and LDL cholesterol values during an average of 33 years of follow-up. Table 1 compares the characteristics of BHS microbiome study participants with high and low lifetime CVD risk profiles. Compared with those with low CVD risk profiles, those with high CVD risk profiles were more likely to be men and, on average, were older and had higher BMI. Although total energy, protein, and animal fat intakes seemed higher and dietary fiber intake lower among participants with high versus low CVD risk profiles, none of the nutrients were significantly different between groups. As expected, glucose, SBP, and LDL cholesterol levels in childhood and adulthood were higher in the high-risk versus the low-risk group.
The association between estimates of α diversity and lifetime CVD risk profile are presented in Table 2 . Increased microbial richness was consistently associated with decreased lifetime CVD risk profile. For example, for each 1 SD increase in the number of observed OTUs, there was a 38% (95% confidence interval, 1%-61%) decreased odds of high lifetime CVD risk profile (P=0.04). Similarly, odds ratios (95% confidence interval) for every SD increase in the Chao 1 index and abundance-based coverage estimator were 0.62 (0.39-0.99) and 0.61 (0.38-0.98), respectively (P=0.04 and 0.05, respectively). Although the P values were slightly attenuated, the magnitudes of associations Associations between individual genera and lifetime CVD risk profile were generally consistent between models (Online Table I ), with moderate pairwise correlation coefficient for Z statistics of 0.60 (P<0.0001) and 0.57 (P<0.0001), for models 1 and 2 and models 1 and 3, respectively. After adjustment for age, sex, and race (model 1), 8 taxa were significant after Bonferroni correction for multiple testing. Within the Bacteroidetes phylum, 3 genera from the family Prevotellaceae significantly associated with CVD risk, including Alloprevotella (P=2.96×10 −6 ), Prevotella 7 (P=7.95×10 −5 ), and Paraprevotella (P=6.48×10 −4 ). Within the Firmicutes phylum, 4 taxa associated with lifetime CVD risk, including 2 genera from the Lachnospiraceae family, Tyzzerella 4 (P=1.51×10 −4 ) and Tyzzerella (P=4.39×10 −4 ) and 2 genera from families Veillonellaceae and Erysipelotrichaceae, Megamonas (P=4.18×10 −5 ) and Catenibacterium (P=1.51×10 −4 ), respectively. In addition, the Enterobacter genus of phylum Proteobacteria was also associated with lifetime CVD risk (P=6.41×10 −8 ). After additional adjustment for BMI (model 2), all 8 of these taxa remained nominally significant (P<0.05), including 5 taxa that retained significance after Bonferroni correction (Alloprevotella, P=6.53×10 −9 ; Prevotella 7, P=5.58×10
Tyzzerella, P=7.83×10
; Megamonas, P=3.41×10 −6 ; and Catenibacterium, P=1.87×10 −4 ). After further adjustment for diet, all genera remained at least nominally significant, except for Paraprevotella and Enterobacter, which no longer associated with CVD risk. Five additional genera attained significance after Bonferroni correction in model 2, including 3 from the Firmicutes phylum (Coprococcus 2, P=1.38×10 −4 ; Megasphaera, P=1.38×10 ). Among these, 2 were nominally significant before BMI adjustment (Methanobrevibacter, P=5.12×10 −3 and Thalassospira, P=3.61×10 −3 ). In model 3, 3 additional genera were significant including 2 from the Bacteroidetes genera (Bacteroidales S24-7, P=2.77×10 −6 and Prevotella 2, P=5.67×10 −5 ) and 1 from the Firmicutes phylum (Christensenellaceae R-7 group, P= P=5.69×10 −4 ). Only Prevotella 2 attained nominal significance in the previous models.
Direction of associations for all 16 taxa achieving significance after Bonferroni correction for multiple testing in any model is shown in Figure ( A) through (C). Among the taxa significantly associated with lifetime CVD risk profile in model 1, Alloprevotella and Catenibacterium were associated with decreased lifetime CVD risk profile (Z=−4.67 and −3.74, respectively) and Paraprevotella, Prevotella 7, Megamonas, Tyzzerella, Tyzzerella 4, and Enterobacter were associated with increased lifetime CVD risk profile (Z=3.41, 3.95, 4.10, 3.52, 3.79, and 5.41, respectively). After additional adjustment for BMI, effect directions for these genera remained consistent except for Megamonas and Paraprevotella, which were significantly and nominally associated with decreased lifetime CVD risk profile, respectively (Z=−4.64 and −2.19, respectively). Aside from Paraprevotella and Enterobacter, which were no longer associated with CVD risk profile after adjusting for diet, association directions for all remaining Model 1 findings were similar in model 3. In model 2, Megasphaera and Ruminococcus seemed to be associated with a decreased lifetime CVD risk profile (Z=−3.81 and −3.48, respectively), whereas Thalassospira, Coprococcus 2, and Methanobrevibacter with an increased lifetime CVD risk profile (Z=3.58, 3.81, and 3.58, respectively). In model 3, Bacteroidales S24-7 and Prevotella 2 (Z=4.69 and 4.03, respectively) were enriched among those with a high lifetime CVD risk profile, whereas Christensenellaceae R-7 (Z=−3.45) was depleted among those with a high lifetime risk profile. Direction of associations for all 16 genera are presented for (A) age, sex, and race; (B) age, sex, race, and body mass index (BMI); and (C) age, sex, race, BMI, total energy intake, and energy-adjusted intake of protein*, animal fat*, and fiber* adjusted analyses. Red shading indicates increased odds of high cardiovascular disease risk profiles, and blue shading indicates decreased odds of high cardiovascular disease risk profiles. Darker shading indicates significance after Bonferroni correction for multiple testing. Dashed circles indicate the scale of (absolute) Z values ranging from 1 to 6. Phyla are indicated next to the outer solid circle. *Adjusted for total energy intake using the residual method. 
Discussion
In the current study, we identified composite measures of α diversity and individual microbial genera associated with lifetime CVD risk profile among BHS participants. We observed consistent inverse associations of measures of microbial richness, but not evenness, with lifetime CVD risk. Although previous studies have reported beneficial associations of the Bacteroidetes phylum and deleterious association of the Firmicutes phylum with CVD risk factors, 3, 32 findings of other studies have been conflicting. 7 At the genera level, we identified 16 taxa significantly associated with lifetime CVD risk profile, including 6 that showed consistent associations in all models examined, including Alloprevotella, Prevotella 2, Prevotella 7, Tyzzerella, Tyzzerella 4, and Catenibacterium. Of note, these findings included genera with opposite effects within the same phyla. For example, among Bacteroidetes, Alloprevotella was associated with decreased lifetime CVD risk, whereas Prevotella 2 and Prevotella 7 were associated with increased lifetime CVD risk in our study. Among the Firmicutes, Tyzzerella and Tyzzerella 4 were enriched among those with high CVD risk profile, whereas Catenibacterium was depleted in this group. These data may help to explain the inconsistency of findings when assessing associations of higher order taxa. Although Methanobrevibacter, Enterobacter, and Thalassospira were enriched among those with high CVD risk profiles in models 1 and 2, these associations were completely attenuated after adjustment for dietary factors, suggesting that diet could confound the observed associations. Several findings seemed relatively inconsistent across models and should be considered with caution in this small sample. For example, both Megamonas and Paraprevotella seemed enriched among those with high CVD risk profile in model 1, depleted in model 2, and unassociated in model 3. Furthermore, Ruminococcus, Coprococcus, and Megasphaera only achieved significance in model 2, whereas Bacteroidales S24-7 and Christensenellaceae R-7 only achieved significance in Model 3. In aggregate, these data add to the accumulating evidence suggesting an important role of the gut microbiota on CVD risk.
α Diversity, measured as microbial richness by the number of observed OTUs, Chao 1 index, and abundance-based coverage estimator, was consistently and inversely associated with lifetime CVD risk in our analyses. These data are in line with previous studies examining other CVD risk factors such as BMI 7, 11 and lipid levels. 11 In contrast, lifetime CVD risk was not associated with α diversity measures incorporating evenness of microbial taxa, such as Shannon, Simpson, and inverse Simpson indices. Similarly, previous studies examining the relation of Shannon Index with CVD risk factors have generally showed null results. 33, 34 These data suggest that the abundance of distinct microbial taxa may be more important than their relative frequency in determining CVD risk.
In the Bacteroidetes phylum, 4 genera of the family Prevotellaceae were identified by the current study. Previous research has linked this group to CVD risk factors including obesity 35, 36 and diabetes mellitus, [37] [38] [39] but the directions of 37 identified an overrepresentation of Prevotellaceae in women with gestational diabetes mellitus versus controls. The current study identified genera within the family Prevotellaceae that had different effects; some were associated with an increased and others with a decreased CVD risk profile. Given the presence of both beneficial and deleterious genera within this phylogenetic family, our data may again suggest that past inconsistencies could have resulted from grouping disparate genera at higher taxonomic levels. Furthermore, our findings indicate that the relation between Prevotellaceae and lifetime burden of CVD risk factors is independent of BMI. Although the previous studies have also identified associations with diabetes mellitus, we are not aware of previous reports, suggesting that the relationship between Prevotellaceae and CVD risk may be independent of BMI. Whether this relationship remains after adjustment for measures of central adiposity is unclear. An additional genera, unidentified bacteria from the Bacteroidales S24-7 family, was also identified from the Bacteroidetes phylum. To the knowledge of the authors, this is the first study to link this genus to CVD risk.
Our results show that 8 genera from the phylum Firmicutes were associated with lifetime CVD risk in the current study. Within the family Lachnospiraceae, we identified genera that were enriched among those with high lifetime CVD risk profile, such as Tyzzerella, Tyzzerella 4, and Coprococcus 2, as well as those that were enriched among the low CVD risk profile group, including Ruminococcus. Similar to findings reported here, Zhang et al 40 identified certain taxa from the family Lachnospiraceae, which were enriched in patients with type 2 diabetes mellitus, and others that were enriched in normal controls. From the family Veillonellaceae, genera Megamonas and Megasphaera were associated with lifetime CVD risk. Megamonas has been reported previously to inversely associate with type 2 diabetes mellitus. 40 After adjustment for BMI, we observed a similar inverse association with lifetime CVD risk profile. The genus Catenibacterium of the Erysipelotrichaceae family was also associated with decreased lifetime CVD risk, which is similar to findings reported by Fu et al 11 of an inverse relation of a genus from this family with BMI. Furthermore, the genus Christensenellaceae R-7 from the family Christensenellaceae, which was not previously associated with CVD risk-related phenotypes, was also identified. Further studies to confirm this association are needed.
We found 2 genera of the phylum Proteobacteria, Thalassospira and Enterobacter, and one of the phylum Euryarchaeota, Methanobrevibacter, to be associated with increased lifetime CVD risk in the current study. These findings are consistent with reports of genera of the phylum Proteobacteria being associated with numerous cardiometabolic traits in human and mouse studies. 38 ,41 For example, Alkanani et al 38 showed an inverse association between Thalassospira and type 1 diabetes mellitus, whereas Enterobacter was experimentally shown to increase obesity risk in mouse models. 41 Methanobrevibacter, the only genus in the domain Archaea assessed in the current study, has also previously been implicated to influence CVD risk, primarily through its association with obesity. 36, 42 Researchers have hypothesized that this taxon may increase obesity risk via its role in increasing polysaccharide fermentation, leading to increased adiposity, and have found support in animal models. 42 The current study found an increased frequency of Methanobrevibacter in participants with high lifetime CVD risk profiles compared with their low-risk counterparts. Although these findings were independent of BMI, the associations were completely attenuated when accounting for diet in the analysis. These data suggest that associations of Thalassospira, Enterobacter, and Methanobrevibacter may be confounded by dietary factors. To the knowledge of the authors, this is the first study to adjust for dietary factors in the analysis.
The current study has several important strengths. The longitudinal BHS design provided a unique opportunity to examine the association between microbiome and lifetime burden of CVD risk factors. Estimation of CVD risk profile was made using carefully collected measures of SBP, LDL cholesterol, and glucose from an average of 9 study visits conducted during ≈33 years of follow-up. Furthermore, stool specimens were collected using a stringent protocol, with sequencing and downstream analyses following guidelines set forth by the Human Microbiome Project. 21 However, certain limitations should also be addressed. The study was conducted among a relatively small subsample of BHS participants. The small sample size may have limited our statistical power to detect other important microbiota and may be responsible for the modestly significant associations of α diversity measures with CVD risk. Furthermore, because the collection of stool specimens occurred after determination of lifetime CVD risk profile, it is not possible to delineate the temporal relation between the observed microbiota-lifetime CVD risk associations. Given the somewhat provisional nature of these findings, replication of the results in independent samples is warranted. In addition, prospective studies are needed to confirm whether the presence of identified microbiota precede alterations in CVD risk profiles. Finally, 16S ribosomal RNA sequencing does not generally provide sequencing resolution beyond the genus level and does not allow for direct functional profiling. Therefore, the current study was limited in its ability to identify specific microbial species and biological pathways that may influence CVD risk. Future research, taking advantage of shot-gun metagenomic DNA sequencing, could contribute important information to this area.
In summary, the current study identified consistent associations of overall microbiota composition and 6 microbial taxa with lifetime CVD risk profile. Microbial richness was depleted among those with a high lifetime burden of CVD risk factors compared with those with a low lifetime burden. Identified genera included those with differing effects, some being enriched and others depleted among participants with high lifetime CVD risk profiles, from phyla including Bacteroidetes and Firmicutes. These cross-sectional data add to the accumulating evidence that microbiota may play an important role in CVD risk. However, further studies examining the prospective relation of the microbiome with CVD health are still needed.
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What Is Known?
• Gut microbes are associated with cardiovascular disease (CVD) risk factors including obesity, type 2 diabetes mellitus, and plasma lipid levels.
• The trimethylamine-oxide metabolite, which can be formed in the liver from a gut microbiota-derived precursor, has been linked to CVD development.
What New Information Does This Article Contribute?
• 
Study Participants
The BHS is a long-term epidemiologic study investigating the natural history of atherosclerosis among a biracial sample (35% black and 65% white) of residents from Bogalusa, Louisiana begun in 1973 by Dr. Gerald Berenson. From 1973 to 2016, seven surveys of children aged 4 to 17 and ten surveys of adults aged 18 to 50 who had been examined previously as children were conducted. The current BHS cohort includes 1,298 participants born between 1959 and 1969 who were screened at least two times during childhood and two times during adulthood for CVD risk factors. A subsample of 203 participants from this cohort who were at highest and lowest estimated lifetime risk of CVD were contacted to determine eligibility for participation in the microbiome study. After excluding 42 participants who had taken antibiotics or probiotics in the past two months, 161 met the eligibility criteria for enrollment. Onehundred twelve of these participants (37% black and 63% white), including 55 with high lifetime CVD risk profile and 57 with low lifetime CVD risk profile, agreed to participate and returned stool specimens for subsequent microbiome characterization and analyses (response rate of 70%).
Measurement of CVD Risk Factors in the BHS Cohort
All BHS examinations have followed nearly identical study protocols. 1, 2 During each study visit, blood pressure (BP) was measured in the morning in triplicate by each of two trained observers using a mercury sphygmomanometer with the participant in a relaxed, sitting position. Systolic and diastolic BP levels were measured as the first and fourth (in children) or fifth (in adults) Korotkoff sounds, respectively. The mean of the six BP values were used to estimate BP at each study visit. Anthropometric measures were obtained by trained staff with BHS participants in light clothing without shoes. Height and weight were measured in duplicate to the nearest 0.1 cm and 0.1 kg, respectively. The mean of height and weight were used to estimate BMI at each study visit. Diet information was collected at two time points in young adulthood using a validated food frequency questionnaire. 3 Participants were instructed to fast for 12 hours prior to blood sample collection. During 1973-1986, cholesterol and triglyceride levels were measured by the use of chemical procedures with a Technicon AutoAnalyzer II (Technicon Instrument Corporation, Tarrytown, New York) according to the Laboratory Manual of the Lipid Research Clinics Program. Since 1987, these variables were determined using the Abbott VP instrument (Abbott Laboratories, North Chicago, Illinois) and on the Hitachi 902 Automatic Analyzer (Roche Diagnostics, Indianapolis, Indiana) afterward by enzymatic procedures. 4 Serum lipoprotein cholesterols were analyzed using a combination of heparincalcium precipitation and agar-agarose gel electrophoresis procedures. 5 Plasma glucose was measured initially by a glucose oxidase method using a Beckman Instant Glucose Analyzer (Beckman Instruments, Palo Alto, California). After 1991, glucose was measured in adults using a multichemistry (SMA20) profile by enzymatic procedures using the multichannel Olympus Au-5000 Analyzer (Olympus, Lake Success, New York).
Estimation of Lifetime CVD Risk Profile
Lifetime CVD risk profile was estimated based on the average of fasting plasma glucose, systolic BP (SBP), and low-density lipoprotein (LDL) cholesterol values from at least four BHS study visits conducted from childhood to adulthood. Lifetime CVD risk groups were identified using a z-score based data reduction technique. For each participant, z-scores for mean lifetime measures of glucose, SBP, and LDL cholesterol were generated. Z-scores for each risk factor were then summed to create an overall lifetime CVD risk score for each participant. Participants were ranked according to risk score, and those with the highest and lowest scores were contacted for participation in the current study.
Microbiome Sequencing and Analysis
Fecal samples were collected at the homes of study participants and returned to BHS investigators within 24 hours of collection, at which time they were stored at -80°C until microbiome characterization. Using methods developed for the Human Microbiome Project, DNA isolation and microbiome sequencing were conducted at the Baylor College of Medicine's Alkek Center for Metagenomics and Microbiome Research. 6, 7 Briefly, genomic bacterial DNA was extracted from fecal samples using the MO BIO PowerSoil DNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA). The 16S rDNA V4 hypervariable region was then amplified by PCR and sequenced on the MiSeq platform using the 2x250 bp paired-end protocol (Illumina ® , San Diego, CA). 8 The read pairs were demultiplexed based on their unique molecular barcodes and overlapping reads were merged using USEARCH v7.0.1001 software. 9 Operational taxonomic unit (OTU) picking was conducted using the QIIME (Quantitative Insights Into Microbial Ecology) software package. 10 OTU picking used an open reference approach, which identified and assigned taxonomies to 16S rRNA gene sequences by matching them to the Silva reference database. 11 The remaining unmatched sequences were clustered according to sequence identity at a similarity cutoff value of 97% using UCLUST. 9 Abundances were recovered by mapping the demultiplexed reads to the identified OTUs.
Since sequencing depth ranged from 4,118 to 13,146 reads per sample, library size was rarefied to the minimum read depth. Subsequently, several alpha diversity measures were estimated based on identified OTUs. 12 Microbial richness, which measures the number of taxa in each sample (or the abundance of microbes), was examined by calculating the number of observed OTUs, Chao 1 index and abundancebased coverage estimator (ACE). 13 Evenness, which measures the relative number of taxa in samples (accounting for the number of times each taxon was observed in a sample), was additionally assessed using the Shannon, Simpson and inverse Simpson indices. 12 An additional quality control step was then conducted to restrict analyses to only those 116 OTUs which comprised ≥0.05% of reads and were present in at least 5% of samples. These OTUs accounted for an average of 95% of total reads per sample. The 116 OTUs were assigned to 75 genera which were examined in further analyses. Processing of microbiome sequence data was conducted using the phyloseq package (V1.15.14) in R.
13
Statistical Analysis
Lifetime CVD risk groups were compared on pertinent characteristics with the use of x 2 tests for categorical variables and t-tests for continuous variables. All alpha diversity measures were examined for normality and log-transformed as needed.
Logistic regression models were employed to examine the associations between each measure of alpha diversity and lifetime CVD risk profile after adjustment for important covariables. The association between individual microbial genera and lifetime CVD risk profile employed a two-step 'partialling out' approach.
14 To accommodate the excessive zero counts and overdispersion of microbiome data, in step 1 a zero-inflated negative binomial model was employed to model each genus. 150 This model assumes that microbiome data for each genus are from a mixture of two separate distributions, one from a negative binomial distribution and the other from a constant distribution generating only zero counts. We model both negative binomial data and the zero count data (the probability of being a zero count) simultaneously with important covariables treated as predictors. The log transformed total genus counts, which varied slightly between participants due to the additional quality control steps subsequent to rarefication, were included in the model as the offset variable. In step 2, the raw residuals from these models, representing the independent effects of each genus, were then compared between CVD risk groups using the Wilcoxon rank sum test. A Bonferroni correction for the 75 genera tested was employed using an alpha threshold of 6.67×10 -4 to determine statistical significance. Three multivariable adjustments were used to test associations of both alpha diversity estimates and individual genera with lifetime CVD risk profile. Model 1 adjusted for age, gender and race. To examine the potentially mediating influence of BMI, a second model adjusting for age, gender, race and BMI was also assessed (Model 2). To determine whether identified associations were consistent after adjustment for dietary factors in this relatively small sample, a third model adjusting for age, gender, race, 
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